ArticleInternational journal of pharmaceutics: X2026
Advanced antibacterial wound management: comparative study of non-antibiotic drug elution and nanoparticle integration.
Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wound infections affect 2% of the global population, causing chronic wounds and healthcare burdens as conventional antibiotics increasingly fail against biofilms. Consequently, attention is shifting toward advanced dressings that simultaneously prevent infection and support tissue regeneration. Among these, fibrous drug delivery systems have emerged as promising platforms for localized and controlled therapeutic delivery. Beyond platform geometry, physicochemical properties of the polymers are paramount in establishing biocompatibility, tunable degradation kinetics, and adequate mechanical integrity. PLGA and PLA/PCL-based nanofibrous platforms exhibit these favorable characteristics, even though they are still limited by issues such as limited control over release kinetics and potential instability of bioactive agents during fabrication. To address the limitations, hybrid platforms combining electrospun nanofibers with drug-loaded nanoparticles have been developed to provide structural integrity and secondary drug reservoirs for sustained release. Here, we developed a dual-carrier hybrid delivery platform to overcome burst release kinetics and achieve sustained local therapeutic levels by integrating microfluidically synthetized nanoparticles with electrospun nanofibrous matrices. To systematically elucidate the role of scaffold structure on the in-vitro performances, two delivery strategies were investigated: (i) direct entrapment of therapeutics within electrospun PLGA and PLA/PCL fibers, and (ii) surface coating of electrospun mats with PLGA nanoparticles. This study uses these approaches to encapsulate a hydrophobic agent, curcumin (CURC), a natural antimicrobial agent with limited solubility, and hydrophilic peptide, bovine lactoferricin (bLFC), which requires protection from enzymatic degradation. The use of these naturally derived compounds offers a promising non-antibiotic strategy to mitigate antibiotic resistance while promoting wound healing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.